Skip to content

Efficacy of KCl Plus 0.9%NaCl Compare With KCl Plus 0.45%NaCl

Efficacy of KCl Plus 0.9%NaCl Compare With KCl Plus 0.45%NaCl for Correction of Hypokalemia in Hospitalized Patients

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02721095
Enrollment
84
Registered
2016-03-28
Start date
2014-08-31
Completion date
2016-09-30
Last updated
2016-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypokalemia

Brief summary

evaluate efficacy and safety of IV administration of potassium chloride (KCl) plus 0.9%NaCl compare with KCl plus half-strength normal saline solution (0.45%NaCl) in correcting hypokalemia

Detailed description

Hypokalemia is frequently encountered in hospitalized patients. Intravenous (IV) potassium repletion with saline is preferred used for initial therapy. However, administration of normal saline (0.9%NaCl) usually provokes sodium and potassium diuresis, thus, it might delay reversal of the hypokalemia. Object of this study : to evaluate efficacy and safety of IV administration of potassium chloride (KCl) plus 0.9%NaCl compare with KCl plus half-strength normal saline solution (0.45%NaCl) in correcting hypokalemia.

Interventions

OTHERKCl plus 0.9%NaCl

comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia

OTHERKCl plus 0.45%NaCl

comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia

Sponsors

Phramongkutklao College of Medicine and Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Serum K+ 2.5-3.49 mmol/L * No life threatening condition from hypokalemia

Exclusion criteria

* Pregnancy * Volume overload, heart failure * Hypotension * Acute kidney injury * Dysnatremia * K+ shift * Salt wasting nephropathy

Design outcomes

Primary

MeasureTime frame
Number of participants with normal serum K as assessed by serum electrolyte24 hours

Countries

Thailand

Contacts

Primary ContactTheerasak Tangwonglert, MD.
theerasak.pmk@gmail.com0897750222

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026